CASI Pharmaceuticals Inc. (CASI)
(Real Time Quote from BATS)
$1.83 USD
-0.11 (-5.67%)
Updated Aug 6, 2025 11:28 AM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, CASI Pharmaceuticals Inc. has a market cap of $23.86M, which represents its share price of $1.94 multiplied by its outstanding shares number of 12.30M. As a small-cap company, CASI's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CASI 1.83 -0.11(-5.67%)
Will CASI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates
Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
Other News for CASI
12 Health Care Stocks Moving In Monday's Intraday Session
FDA Approves IND Application for CASI's CID-103, Advancing AMR Treatment
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft ...
Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)